TC BioPharm Ltd at LD Micro Invitational Conference Transcript
Next on the floor, we have Mr. Bryan Kobel from TC BioPharm.
I haven't said anything yet. So hold the applause until you have enjoyed the story, I think. Appreciate you guys coming in here to hear the story. TC BioPharm is the global leader in gamma delta T cell therapies. We'll get to that, what that means later. Forward-looking statements.
So the company right now is developing a platform technology around allogeneic gamma delta T cells or off-the-shelf cell therapies for oncology. Allogeneic, means we take donor-derived materials, isolate, expand, and then inject that material back into patients specifically. So -- versus autologous, which would be donor-derived -- or patient derived.
We recently repositioned the company for a clinical trial focus to the FDA and a streamlined efficiency. We do expect to file our IND with the US FDA for our AML trial in Q3 of 2023 or this year. That product has FDA orphan drug status, which was granted about three years ago off of our
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
